Chronotherapy: Timing Medicines and Treatments

Read this first

Chronotherapy is the study of whether giving a medicine or treatment at a particular time of day changes how well it works or how safe it is. This page reports research findings only. It is not advice about when to take any medicine. Do not change the time you take a prescribed medicine, or stop it, because of this page. Ask the prescriber or pharmacist, who know your medicines, your other conditions and the product's label. See also Talking With a Health Professional and How Medication Interactions Work.

Evidence labels: established, promising but limited, mixed, insufficient evidence, no good evidence of benefit. See How We Label Evidence in Specialty Topics.

Why timing might matter

The body's rhythms affect functions such as hormone release, appetite and digestion, and temperature. [1] For cancer immunotherapy, researchers point to circadian mechanisms in immune-cell functions and trafficking as the reasoning for testing timing. [2] The question is whether that reasoning holds up in trials with clinical outcomes. The answer differs by treatment.

Blood pressure medicines: the largest trials

No good evidence of benefit from evening dosing over morning dosing (in the usual-medicines trial). The UK TIME study randomly assigned 21,104 adults with hypertension to take all their usual antihypertensive medicines in the morning or in the evening and followed them for a median 5.2 years. [3] The primary outcome (vascular death or hospital admission for non-fatal heart attack or stroke) occurred in 3.4% of the evening group and 3.7% of the morning group (hazard ratio 0.95, 95% CI 0.83 to 1.10; p=0.53). [3] No safety concerns were identified. [3] The authors concluded evening dosing was not different from morning dosing for major cardiovascular outcomes. [3]

Earlier studies had suggested bedtime dosing might do better. A 2022 International Society of Hypertension position paper reviewed eight outcome studies of bedtime dosing and judged all had major methodological or other flaws and a high risk of bias. [4] A 2023 meta-analysis of five trials found bedtime dosing associated with fewer myocardial infarctions (RR 0.80) but no significant difference in other outcomes, and called the evidence uncertain. [5] A 2026 meta-analysis of five studies (36,477 patients) found no significant differences in major adverse cardiovascular events or mortality, with very high heterogeneity (I² above 90%). [6] Overall: mixed earlier signals, with the largest high-quality trial showing no difference. A drug-specific label or a clinician's instruction still governs any individual case, which this page cannot assess.

Cancer immunotherapy: observational signal, trials needed

Insufficient evidence (observational only). A 2024 study-level meta-analysis of 13 studies (1,663 patients, mostly non-small-cell lung cancer, kidney cancer and melanoma) compared earlier versus later time-of-day infusions of immune checkpoint inhibitors. It reported longer overall survival (HR 0.50, 95% CI 0.42 to 0.58) and progression-free survival in the early group. [2] The authors themselves state that prospective randomized trials are needed before recommendations on circadian timing can be made. [2] A separate 2024 meta-analysis in metastatic kidney cancer pooled four reports and found a similar direction (HR for survival 0.62), again calling for randomized trials. [7] Comparisons of this kind can be affected by confounding, meaning other differences between patients who happened to be treated earlier or later. Do not ask to change an appointment time because of this page; talk with the care team.

Other treatments

Proper evidence not found in the sources reviewed for this page on timing of other medicines (for example cholesterol, diabetes or steroid treatments). This page did not search that literature, so the gap is in this page and not necessarily in the research.

How to judge a chronotherapy claim

• Is the evidence a randomized trial, or retrospective records?
• Is the outcome a clinical event (heart attack, survival) or a biomarker such as a blood pressure reading at night? See Biomarkers vs Clinical Outcomes.
• Is the claim about one named drug, or being generalized to "all medicines"?
• Does it come from a seller of "timing" supplements? No supplement-timing evidence was reviewed here; see Evaluating Safety Claims.

Related timing topics: Circadian Biology Explained, Chrononutrition Research.